Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)

AstraZeneca15 enrolled

Overview

The purpose of this study is to investigate the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Metabolic Syndrome Dyslipidemia

Interventions

RosuvastatinDRUG

Eligibility

Sex: MALEMin age: 45 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * males aged 45-65 * insulin resistance * central obesity * LDL-C \<6 mmol/L * plasma triglycerides \>=1.7 and ≤5.5 mmol/L * HDL-C ≤1.2 mmol/L. Exclusion Criteria: * total cholesterol \>7mmol/L * pre-existing cardiovascular disease, diabetes, proteinuria or renal failure

Locations (1)

Research Site

Melbourne, Victoria, Australia

Outcomes

Primary Outcomes

Determine the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.

Secondary Outcomes

Determine the effect of treatment with rosuvastatin on:

- cholesterol esterification by measuring plasma lecithin:cholesterol acyl transferase concentration and capacity to esterify cholesterol, one of the stops in RCT.

- plasma concentration of cholesterol ester transfer protein and capacity to transfer cholesterol from HDL-C to apoB-containing lipoproteins, one of the steps in RCT.

- plasma concentration of preβ1-HDL.

- plasma concentration of LDL cholesterol, HDL-C and apoA-1.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.